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Aim To determine the prevalence of American College 
of Rheumatology (ACR) and Systemic Lupus International 
Collaborating Clinics (SLICC) classification criteria among 
systemic lupus erythematosus (SLE) patients; to determine 
disease activity and severity; and to investigate the correla-
tion of classification criteria with disease activity, and of dis-
ease activity and damage index with disease duration.
Methods We performed a cross-sectional study on 110 
SLE patients from the Division of Rheumatology and Clini-
cal Immunology, University Hospital Centre Rijeka, Croatia 
in the period from September to December 2013 and de-
termined disease duration and the total number of ACR 
and SLICC classification criteria. Disease activity was as-
sessed by Systemic Lupus Erythematosus Disease Activity 
Index (SLEDAI) index and organ damage by Systemic Lu-
pus International Collaborating Clinics/American College 
of Rheumatology (SLICC/ACR) damage index.
Results The number of SLICC classification criteria met per 
patient was significantly higher than the number of ACR 
criteria (7 [IQR 6-8] vs 5 [IQR 4-6], P < 0.001). Moderate corre-
lations were detected between the number of SLICC clas-
sification criteria and disease activity index, both in case 
of active (r = 0.48, P = 0.003) and inactive disease (r = 0.43, 
P < 0.001). We neither found a correlation between the 
number of ACR criteria and disease activity nor between 
disease activity and disease duration. However, there was 
a good correlation between SLICC/ACR damage index and 
disease duration (r = 0.63, P < 0.001).
Conclusion New SLICC classification criteria correlate with 
disease activity because they capture more manifestations 
also included in the SLEDAI index. Patients with longer dis-
ease duration had a larger damage index score.
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Systemic lupus erythematosus (SLE) is a chronic inflam-
matory disease affecting a number of organs and organ 
systems (1,2). The first classification criteria for SLE were 
developed in 1971, revised in 1982 (3), and adopted by 
the American College of Rheumatology (ACR) in 1997 (1). 
These criteria were developed and validated for the classifi-
cation of patients with a longstanding established disease. 
Although developed as “classification criteria,” ACR criteria 
have been extensively used as diagnostic criteria. For di-
agnosis of SLE, the patient must satisfy at least 4 of 11 ACR 
classification criteria. These criteria were revised and vali-
dated by the Systemic Lupus International Collaborating 
Clinics (SLICC) group in 2012 (4), and according to SLICC, 
the patient must satisfy at least 4 of 17 SLICC classification 
criteria, including at least one clinical and one immuno-
logic criterion. In Croatia only two studies so far have deter-
mined the prevalence of ACR classification criteria among 
patients with SLE (5,6).
The Systemic Lupus Erythematosus Disease Activity In-
dex (SLEDAI) is one of the standard scales utilized to as-
sess disease activity (7-9). A few modifications of SLEDAI 
index have been made (Mex-SLEDAI, SLEDAI-2K, SELENA 
SLEDAI), one of them in the Safety of Estrogens in Lupus Er-
ythematosus National Assessment (SELENA) trial known as 
the SELENA-SLEDAI system (10). Despite the modifications 
of some of the descriptors, SELENA SLEDAI is very similar to 
SLEDAI-2K. The maximum possible score of SELENA SLEDAI 
index is 105.
The Systemic Lupus International Collaborating Clinics 
(SLICC/ACR) damage index has been developed to assess 
irreversible damage in SLE patients, independently of its 
cause (7,11,12). The maximum possible score is 47. The 
SLICC damage score gradually increases over time (13,14) 
and patients with higher damage scores early in the course 
of disease have been associated with poor prognosis and 
increased mortality (15,16).
SLICC classification criteria improved the clinical relevance 
of the ACR criteria, incorporated recent findings on the im-
munology of SLE, and resolved several problems attrib-
uted to the ACR criteria (4). As SLICC classification criteria 
have an impact on clinical practice, we wanted to see if 
they correlated with disease activity. It is known that dis-
ease duration in SLE patients affects organ damage (13,14), 
but data on the influence of disease duration on disease 
activity are missing. The aim of this study was 1) to deter-
mine the prevalence of each of the ACR and SLICC classi-
fication criteria and make a comparison between them, 2) 
to determine the correlation between both classification 
criteria and disease activity and 3) to determine the cor-
relation between disease activity and damage index with 
disease duration.
PAtieNtS AND MethoDS
Patients
We performed a cross-sectional analysis of SLE patients 
from the Division of Rheumatology and Clinical Immu-
nology, University Hospital Centre Rijeka, Croatia who 
fulfilled at least 4 ACR classification criteria and were ex-
amined by Division’s specialists from September to De-
cember 2013. Patients with fewer than 4 ACR classifica-
tion criteria were not included. The patients either had 
a previously established diagnosis of SLE or were diag-
nosed at the last visit. Time limit of the study was set to 
3 months because common outpatient examination pe-
riod lasts for an average of 3 months. The study included 
all 110 consecutive patients with SLE who were exam-
ined by physicians at our hospital center during the peri-
od of 3 months and their medical records were analyzed. 
Among patients not included in the study, but examined 
in this period, 9 patients fulfilled ≥4 SLICC classification 
criteria, but did not fulfill 4 ACR classification criteria. All 
our patients included in the study fulfilled at least 4 ACR 
classification criteria while the number of fulfilled SLICC 
criteria was not an inclusion criterion. Median age of all 
patients was 47 years (range 20-75). There were 97 (88%) 
female and 13 (12%) male patients. Median age of all pa-
tients at diagnosis was 37 years (range 11-74). Median of 
SLE duration was 9 years (range 5-13).
Methods
For each patient the cumulative and individual frequency 
of each of the ACR and SLICC classification criteria, SEL-
ENA SLEDAI components, and SLICC/ACR damage items 
were determined. ACR classification criteria revised 1982 
with reference to their 1997 updated version and new 
SLICC classification criteria were used (1,3,4). ACR and 
SLICC classification criteria present at the last visit were 
taken into consideration, as well as all the criteria from 
the time when SLE diagnosis was established. All the cri-
teria from the time when SLE diagnosis was made were 
captured. Disease activity was assessed using SELENA 
SLEDAI score-weighted scale for 24 parameters. SLE pa-
tients with SLEDAI score ≥6 were considered to have 
active disease. Damage was assessed by SLICC/ACR 
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damage index. It is defined for 12 organ systems and had 
to be continuously present for at least 6 months. Damage 
score can only remain stable over time or increase, to a 
maximum of 47 points (11).
Data were analyzed using the STATISTICA software, ver-
sion 12.0 (StatSoft, Inc., Tulsa, OK, USA). The normality of 
distribution was tested by Kolmogorov-Smirnov test. Non-
normally distributed variables are shown as medians with 
interquartile range (IR). Nominal variables are presented as 
frequencies or percentages. For non-normally distributed 
values we used Mann-Whitney U-test and for normally dis-
tributed variables, Spearman rank correlation coefficient r 
and r2 value. Statistical significance level was P < 0.05. Cor-
relations from 0 to 0.25 (or -0.25) were interpreted as no 
relation, those from 0.25 to 0.50 (or -0.25 to -0.50) as a fair 
degree of relation, those from 0.50 to 0.75 as a moderate 
to good relation, and those greater than 0.75 (or -0.75) as a 
very good to excellent relation.
ReSultS
The prevalence of each ACR classification criterion (Figure 1) 
and new SLICC criterion (Figure 2) for SLE was determined 
and the most frequently observed criteria were positive 
ANA titer (in 94% of patients), immunologic disorder (91%), 
arthritis (90%), anti-dsDNA (85%), low complement (85%), 
hematologic disorder (79%), leukopenia (78%), and acute 
cutaneous lupus (73%). For 11 (10%) SLE patients, there 
were no data about anticardiolipin antibodies. Median 
number of ACR classification criteria met per patient was 5 
(IQR 4-6) and of SLICC classification criteria was 7 (IQR 6-8) 
(Mann-Whitney U test, P < 0.001). Thirty-six patients (33%) 
had active SLE (SELENA SLEDAI score ≥6). Median SELENA 
SLEDAI score of all patients was 2 (IQR 0-7), while median 
SELENA SLEDAI score of patients with active SLE was 8 (IQR 
7-10). We found no correlation between ACR classification 
criteria and SELENA SLEDAI score either in active (r = 0.23, 
P = 0.173) or inactive (r = 0.24, P = 0.041) disease. However, 
moderate correlations were detected between SLICC clas-
sification criteria and disease activity index, both in active 
(r = 0.48, P = 0.003) and inactive disease (r = 0.43, P < 0.001) 
(Table 1). The most frequently observed clinical and labora-
tory components of SELENA SLEDAI index were low com-
plement in 53%, increased DNA binding in 35%, arthritis in 
27%, and rash in 15% of patients (Figure 3). Median SLICC/
ACR damage index score of all patients was 2 (IQR 0-3). The 
most frequently observed components were osteoporosis 
with fracture or vertebral collapse and cranial or periph-
eral neuropathy in 22%, any cataract ever in 21%, pleural 
fibrosis in 13%, and malignant diseases in 12% of patients 
(Figure 4). Among SLE patients with malignant diseases 
we recorded 4 gynecologic cancers, 2 breast cancers, 1 
tABle 1. Spearman rank correlation coefficients r and r2, and 
their respective level of statistical significance for association 
between the number of ACR classification criteria, SliCC classi-
fication criteria, SliCC/ACR damage index, and SeleNA SleDAi 
score in groups with active (n = 36) and inactive (n = 74) Sle
SeleNA SleDAi score
Active Sle inactive Sle
r r2 P r r2 P
ACR number of CC 0.23 0.05 0.173 0.24 0.06  0.041
SLICC number of CC 0.48 0.23 0.003 0.43 0.18 <0.001
SLICC/ACR damage index 0.18 0.03 0.291 0.01 0.00  0.817
*Abbreviations: ACR – American College of Rheumatology; CC – clas-
sification criteria; SliCC – Systemic lupus international Collaborat-
ing Clinics; SliCC/ACR – Systemic lupus international Collaborating 
Clinics/American College of Rheumatology; SeleNA SleDAi – Safety 
of estrogens in lupus erythematosus National Assessment Systemic 
lupus erythematosus Disease Activity index; Sle – systemic lupus 
erythematosus.
FiguRe 1. the prevalence of the American College of Rheuma-
tology (ACR) classification criteria for systemic lupus erythema-
tosus (Sle) in 110 Sle patients.
FiguRe 2. the prevalence of Systemic lupus international 
Collaborating Clinics (SliCC) classification criteria for systemic 
lupus erythematosus (Sle) in 110 Sle patients.
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melanoma, 1 basalioma, 1 kidney cancer, 1 lung cancer, 1 
myeloproliferative neoplasm, 1 Hürthle cell cancer, and 1 
metastatic brain tumor. This group had significantly longer 
disease duration than patients without malignant diseases 
(median 15 years [IQR 9-20] vs 9 years [IQR 5-13], P = 0.042). 
The correlation between activity score index and duration 
of disease was not found (r = -0.13, P = 0.172), although a 
good correlation between disease duration and SLICC/
ACR damage index was recorded (r = 0.63, P < 0.001).
DiSCuSSioN
Our study found a moderate correlation between the num-
ber of new SLICC classification criteria and SLEDAI disease 
activity index, both in active and inactive disease. However, 
there was no correlation between the number of ACR clas-
sification criteria and disease activity index. SLICC classifi-
cation criteria correlate with disease activity because they 
capture more clinical and laboratory findings also involved 
in SLEDAI index. In comparison to ACR criteria, SLICC cri-
teria and SLEDAI index capture more neurological mani-
festations of disease (4,7). SLICC neurological disorder was 
observed in 24% of our patients, while ACR neurological 
disorder in only 5%. SLICC criteria and SLEDAI index also 
include nonscarring alopecia, which is not included in ACR 
criteria (4,7). Nonscarring alopecia was found in 22% of our 
patients. In comparison to ACR criteria, SLICC criteria and 
SLEDAI index include separately leucopenia and thrombo-
cytopenia, which are important laboratory parameters of 
disease activity (4,7). In our study, ACR hematologic disor-
der was detected in 79%, leucopenia as a separate SLICC 
criterion in 78%, and trombocytopenia in 13% of patients. 
Low complement, found in a large number of our patients 
(85%), is not included in ACR criteria, but is in SLICC crite-
ria (4). As a laboratory characteristic of disease activity, it 
contributes to correlation between new SLICC criteria and 
activity score index.
The prevalence of the ACR classification criteria in our pa-
tients was similar to that in previous studies (3,5,17-19). In 
comparison to other European studies, we detected more 
arthritis (90%) but less discoid rash (1%) and photosensi-
tivity (25%).
Our study showed that patients with longer disease du-
ration had a larger damage index score. In general, dam-
age score remains the same over time or increases (20). 
Gladman et al have shown a gradual increase in damage 
score over a period of 15 years (13), while another study 
showed an increase over a period of 5 years in an aver-
age 30% of patients (20). In our study the most frequent-
ly observed feature of SLICC/ACR damage index was os-
teoporosis with fracture or vertebral collapse. It has been 
shown that the frequency of fractures in women with SLE 
is between 5.0 and 21.4% (21,22). Our analysis detected 
malignancy as the fifth most represented component of 
SLICC/ACR damage index. Another study found a greater 
number of cancer cases in SLE patients (10%-15%) than 
in the general population, due to the combination 
FiguRe 3. the prevalence of Systemic lupus erythemato-
sus Disease Activity index (SleDAi) components in 110 Sle 
patients.
FiguRe 4. the prevalence of Systemic lupus international Collaborating Clinics/
American College of Rheumatology (SliCC/ACR) damage index components in 110 
systemic lupus erythematosus (Sle) patients. “other” include premature gonadal 
failure, pericarditis for 6 months or pericardiectomy, transverse myelitis, avascular 
necrosis, osteomyelitis, stricture of upper gastrointestinal tract surgery ever. gF – 
glomerular filtration.
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of baseline immune system defects and exposure to im-
munosuppressive medications (23). Increased risk of he-
matologic cancers and decreased risk of hormone-sensi-
tive cancers caused by alterations in estrogen metabolism 
was reported in several studies (23,24). In contrast to this, 
we detected hormone-sensitive cancers in 6 SLE patients, 
while hematologic cancer was found in only one patient.
Our study has several limitations. It was conducted in only 
one center and we did not analyze if patients with active 
SLE also developed a higher damage score index. Data 
about performance of the new SLICC classification criteria 
in childhood SLE have been recently published (25). Our 
study showed that new SLICC classification criteria cor-
related with disease activity because they included more 
manifestations of SLE also involved in SLEDAI activity in-
dex. Although they were developed as classification crite-
ria, SLICC criteria are more consistent and have substantial 
impact on clinical practice and probably in the future they 
will be used as diagnostic criteria. However, more research 
on a larger number of patients is needed in order to obtain 
more representative results.
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